NEW YORK (GenomeWeb News) – MorphoSys subsidiary AbD Serotec said today that it is collaborating with e2v Biosensors to develop a new protein-quantification system for point-of-care and near-patient testing.

 

The agreement builds on an initial project that the companies began in 2006 to use AbD’s HuCAL GOLD recombinant antibody technology with e2v’s Visucare single-antibody immunoassay technology.